Jeff L. Vacirca - 17 Jun 2025 Form 3 Insider Report for Caris Life Sciences, Inc.

Role
Director
Signature
/s/ J. Russel Denton, Attorney-in-Fact
Issuer symbol
CAI on Nasdaq
Transactions as of
17 Jun 2025
Net transactions value
$0
Form type
3
Filing time
17 Jun 2025, 21:36:53 UTC
Previous filing
12 Jun 2024
Next filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Vacirca Jeff L Director C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING /s/ J. Russel Denton, Attorney-in-Fact 17 Jun 2025 0001724161

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CAI Common Stock 16,129 17 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CAI Stock Option 17 Jun 2025 Common Stock 25,000 $17.16 Direct F2
holding CAI Stock Option 17 Jun 2025 Common Stock 75,000 $19.44 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 16,129 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreement.
F2 The stock option vests in five substantially equal annual installments beginning on February 23, 2023.
F3 The stock option vests in five substantially equal annual installments beginning on November 7, 2025.

Remarks:

Exhibit 24 - Power of Attorney.